BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics Corp., a biotech firm advancing cancer immunotherapies, has announced a $5 million registered direct offering to sell common shares and warrants to healthcare-focused investors, including an existing investor and a company director. The proceeds are earmarked for corporate purposes such as a Phase 3 breast cancer study, R&D, and general working capital. The offering, subject to customary closing conditions, is expected to close around May 17, 2024.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
